



UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

JAN 22 2001

RECEIVED

#77619  
38369-169219  
seg

the application of:

Andrew P. MAZAR *et al.*

Appl. No. 09/670,537

Filed: 27 September 2000

For: DIAGNOSTIC PROBES AND  
THERAPEUTICS TARGETING uPA  
AND uPAR

Art Unit: 1619

Examiner: Jones, Dameron L.

Atty. Docket No. 38369-169219

Customer No.



26694

PATENT TRADEMARK OFFICE

**RESPONSE TO COMMUNICATION REGARDING SEQUENCE LISTING**

**PRELIMINARY AMENDMENT and**

**STATEMENT TO SUPPORT FILING AND SUBMISSION OF SEQUENCE LISTING IN  
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

This responds to the communication from the PTO mailed 17 December 2001, noting that Applicants had not yet complied with the requirements of 37 CFR §§ 1.821-1.825, as they had not filed a Paper or CRF Sequence Listing nor a Statement indicating identity between the paper and CRF Sequence Listings.

Applicants enclose herewith a CRF Sequence Listing and paper Sequence Listing.

The specification is hereby amended to include or correct reference to SEQ ID NO's.

IN THE SPECIFICATION:

Please amend the specification as follows: